Os 85 melhores médicos do mundo para o tratamento de anemia aplástica

O Dr. Avichai Shimoni é o diretor de transplante de medula óssea no Sheba Medical Center. Ele trata cânceres sanguíneos complexos. Concluiu uma bolsa de estudos especializada no MD Anderson Cancer Center. O Dr. Shimoni utiliza transplantes alogênicos e autólogos para pacientes de alto risco. Ele é professor e presidente de Hematologia na Universidade de Tel Aviv.

• Nomeado entre os melhores médicos de Israel pela Forbes para 2025 e 2026.
• Autor de mais de 250 artigos científicos sobre terapias celulares e transplantes.
• Fornece terapia de células T com CAR para leucemia, linfoma e mieloma múltiplo.
• Trabalha no Sheba Medical Center, um dos 10 melhores hospitais do mundo segundo a Newsweek.

A Dra. Hila Magen é uma hemato-oncologista israelense líder no Sheba Medical Center. Ela chefia a Unidade de Mieloma Múltiplo e Amiloidose. A Dra. Magen é especializada no tratamento de distúrbios complexos de células plasmáticas e mieloma de alto risco. Ela é pesquisadora principal de programas inovadores de terapia CAR-T no local de atendimento. Seu trabalho traz imunoterapias avançadas para o cuidado clínico de rotina.

• Autora de mais de 100 publicações científicas e estudos fundamentais sobre mieloma.
• Completou fellowships no MD Anderson e na Universidade de Ciências Médicas do Arkansas.
• Realiza terapia com células CAR-T e transplantes de medula óssea.
• Trabalha no Sheba Medical Center, classificado em 7º lugar mundial em 2026 pela Newsweek.

Realizou mais de 3.500 transplantes de medula óssea – reconhecido pela Forbes como um dos melhores médicos em 2018.

• _doctor_3609_anos_ de experiência em hematologia pediátrica
• Especializado no tratamento de crianças com doenças raras do sangue
• Conhecido entre os pacientes como 'aquele que transplanta a vida'
• Trabalha no Hadassah Medical Center

A Dra. Irina Zaidman é especializada em transplante de medula óssea pediátrico – um tratamento crítico para anemia aplástica – no Hadassah Medical Center.

• Fellowship em transplante de medula óssea pediátrico no Hospital for Sick Children em Toronto
• Membro do conselho da Sociedade Israelense de Hematologia e Oncologia Pediátrica
• Membro de sociedades europeias e americanas de transplante de medula óssea
• Pesquisas publicadas sobre transplantes de medula óssea pediátricos

A Dra. Iris Kventsel é hemato-oncologista pediátrica e especialista em transplante de medula óssea no Sheba Medical Center. Ela trata sarcomas infantis, como o sarcoma de Ewing e o osteossarcoma, no Hospital Infantil Edmond e Lily Safra. A Dra. Kventsel integra terapias direcionadas com tratamentos celulares para cânceres infantis complexos. Ela faz parte do corpo docente da Faculdade de Medicina da Universidade de Tel Aviv.

• Especializada em transplante de medula óssea e terapia com células CAR-T para pacientes pediátricos.
• Pesquisa a predisposição genética ao câncer, incluindo a síndrome de Li-Fraumeni e genes de suscetibilidade.
• Publica em periódicos importantes sobre biologia de células-tronco e oncologia cirúrgica (HIPEC).
• Trabalha no Sheba Medical Center, classificado entre os 10 melhores hospitais do mundo.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

O Dr. Spielberg é um onco-hematologista dedicado no Assuta Medical Center, especializado em distúrbios sanguíneos como a anemia aplástica.

• Ele se concentra tanto no diagnóstico quanto no planejamento abrangente do tratamento
• Especialista no manejo de síndromes de falência da medula óssea
• Trabalha no maior hospital privado de Israel, o Assuta Medical Center
• Oferece atendimento personalizado para condições hematológicas complexas

Assoc. Prof. Priv.-Doz. Dr. Alexander W. Hauswirth is a specialist in internal medicine and haemato‑oncology at JUVENIS. Since 2010, he has served as the lead senior physician for Haematology/Haemostaseology and Oncology at the Clinic for Internal Medicine I, Medical University of Vienna/AKH Vienna, Austria’s largest hospital.

He earned his medical degree from the University of Vienna in 1999. He received the venia docendi in 2010 and was appointed Associate Professor in 2012. He completed an additional haemato‑oncology qualification in 2014. As a Schrödinger Fellow in Salamanca in 2009–2010, he researched CLL stem and precursor cells. He has published regularly since 2000.

Accreditations include Austrian Medical Chamber diplomas in emergency medicine (since 2009) and sports medicine (2018). Awards include the Schrödinger Fellowship (2009), the ÖGHO award (2009), and the European Society of Chemotherapy poster award (2003). Clinical focus: anaemias, leukaemias, lymph node disorders, clotting and anticoagulation, and pre‑operative clearance. Languages: German and English.

O Dr. Aydogdu fez contribuições significativas através de apresentações e discussões, particularmente sobre o tema crítico da detecção precoce do cancro em crianças.

• Especializado em hematologia e oncologia pediátrica
• Foca-se na detecção precoce e tratamento de cancros infantis
• Ativo em investigação médica e apresentações

O Professor Bosch é um líder de renome mundial em Leucemia Linfocítica Crónica (LLC), com mais de 100 artigos publicados e participação contínua em mais de 80 ensaios clínicos.

• Chefiar a Hematologia no Hospital Universitário Vall d'Hebron
• Especializar-se em novos tratamentos para distúrbios linfoproliferativos
• Investigação de doutoramento focada em distúrbios linfoproliferativos crónicos
• Presidir ao grupo espanhol de estudo da LLC (GELLC)
• Bolsa de pós-doutoramento na Universidade de Columbia, Nova Iorque

A Prof. Elke Jaeger é chefe de Oncologia e Hematologia no Nordwest – uma especialista de topo em sarcomas, reconhecida pelo ranking Focus.

• _doctor_502_anos_ de prática especializada em oncologia e hematologia
• Reconhecida como uma das melhores oncologistas da Alemanha
• Especialidade em tratar doenças raras do sangue

O Professor Associado Rafet Eren é especializado em hematologia, com mais de 50 publicações em revistas internacionais, refletindo uma profunda experiência em doenças do sangue.

• Doutorado em Hematologia pelo Hospital de Treinamento e Pesquisa de Istambul
• Membro da Sociedade Europeia de Hematologia
• Vencedor do prémio Jovem Investigador em 2016
• Fluente em inglês para consultas internacionais

O Prof. Kaynar lidera o Departamento de Hematologia e Transplante de Medula Óssea no Hospital Universitário Medipol Mega, com vasta experiência em transplantes de medula óssea e anemia aplástica.

• Ex-chefe de Hematologia na Universidade Erciyes
• Dirigiu a Unidade de Aférese por 16 anos
• Pesquisador visitante no Centro de Transplante de Medula Óssea da Universidade Duke
• Especializado em hematologia benigna e maligna

O Dr. Apak especializa-se em hematologia-oncologia pediátrica com _doctor_6792_ anos_ de experiência, focando-se em transplantes de medula óssea e terapia com células CAR-T no Hospital Universitário Biruni.

• Chefe da Divisão de Hematologia-Oncologia Pediátrica na Universidade de Istambul-Cerrahpaşa
• Autor de 75 publicações internacionais em oncologia pediátrica
• Editor assistente do periódico Turkish Pediatrics Archives
• Membro do conselho da Sociedade Turca de Pediatria

O Dr. Eckhart Weidmann chefia o setor de Hematologia na Clínica Nordwest, especializado no tratamento de doenças do sangue com mais de _doctor_501_anos_ de prática.

• Especialista em linfoma não Hodgkin e anemia aplástica
• Professor com vasta experiência acadêmica e clínica
• Lidera uma equipe dedicada ao tratamento de doenças do sangue